Eli Lilly (LLY) revenue: $65.2B
Eli Lilly reported $65.2B of revenue for the year ended Dec 31, 2025, up 44.7% from $45B a year earlier.
From Eli Lilly's filings with the SEC · Read the filing · LLY stock page
Eli Lilly revenue by year
#66 of 3,622 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $65.2B | +45% |
| Dec 31, 2024 | $45B | +32% |
| Dec 31, 2023 | $34.1B | +20% |
| Dec 31, 2022 | $28.5B | +1% |
| Dec 31, 2021 | $28.3B | – |
Revenue of similar companies
Companies in the same industry as Eli Lilly, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| Johnson & Johnson | $94.2B | Dec 28, 2025 |
| Eli Lilly | $65.2B | Dec 31, 2025 |
| Merck | $65B | Dec 31, 2025 |
| Pfizer | $62.6B | Dec 31, 2025 |
| AbbVie | $61.2B | Dec 31, 2025 |
| Bristol Myers Squibb | $48.2B | Dec 31, 2025 |
| Abbott Laboratories | $44.3B | Dec 31, 2025 |
Questions and answers
What is Eli Lilly's revenue?
Eli Lilly reported $65.2B of revenue for the year ended Dec 31, 2025, up 44.7% from $45B a year earlier.
Numbers as reported in Eli Lilly's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology